Page 31 - Read Online

Li et al. Hepatoma Res 2020;6:15 I http://dx.doi.org/10.20517/2394-5079.2019.34 Page 9 of 13

REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Gosalia AJ, Martin P, Jones PD. Advances and future directions in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol
(N Y) 2017;13:398-410.
3. Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, et al. Systemic therapy for intermediate and advanced hepatocellular carcinoma:
sorafenib and beyond. Cancer Treat Rev 2018;68:16-24.
4. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable
hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73.
5. Bruix J, Qin S, Merle P, Granito A, Huang YH, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
6. Finn RS, Merle P, Granito A, Huang YH, Bodoky G, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib
for HCC: additional analyses from the phase III RESORCE trial. J Hepatol 2018;69:353-8.
7. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, et al. Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med 2018;379:54-63.
8. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006;43:S54-62.
9. Crispe IN. The liver as a lymphoid organ. Ann Rev Immunol 2009;27:147-63.
10. Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016;13:88-110.
11. Kubes P, Jenne C. Immune Responses in the Liver. Ann Rev Immunol 2018;36:247-77.
12. Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J
Hepatol 2015;62:1420-9.
13. Lu C, Rong D, Zhang B, Zheng W, Wang X, et al. Current perspectives on the immunosuppressive tumor microenvironment in
hepatocellular carcinoma: challenges and opportunities. Mol Cancer 2019;18:130.
14. Cherrier DE, Serafini N, Di Santo JP. Innate lymphoid cell development: a T cell perspective. Immunity 2018;48:1091-103.
15. Peng H, Tian Z. Re-examining the origin and function of liver-resident NK cells. Trends Immunol 2015;36:293-9.
16. Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol
2018;18:671-88.
17. Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol 2015;15:243-54.
18. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and inhibitory receptors of natural killer cells. Immunol
Cell Biol 2011;89:216-24.
19. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation
and inhibition. Ann Rev Immunol 2013;31:227-58.
20. Cai L, Zhang Z, Zhou L, Wang H, Fu J, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism
in hepatocellular carcinoma patients. Clin Immunol 2008;129:428-37.
21. Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
Cell Mol Immunol 2015;12:292-302.
22. Sun C, Xu J, Huang Q, Huang M, Wen H, et al. High NKG2A expression contributes to NK cell exhaustion and predicts a poor
prognosis of patients with liver cancer. Oncoimmunology 2017;6:e1264562.
23. Sun H, Huang Q, Huang M, Wen H, Lin R, et al. Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of
human hepatocellular carcinoma. Hepatology 2019;70:168-83.
24. Zheng X, Qian Y, Fu B, Jiao D, Jiang Y, et al. Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nat
Immunol 2019;20:1656-67.
25. Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, et al. Myeloid derived suppressor cells inhibit natural killer cells
in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology 2009;50:799-807.
26. Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular
carcinoma is mediated by CD48/2B4 interactions. Hepatology 2013;57:1107-16.
27. Li T, Yang Y, Hua X, Wang G, Liu W, et al. Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and
IDO. Cancer Lett 2012;318:154-61.
28. Tian Z, Chen Y, Gao B. Natural killer cells in liver disease. Hepatology 2013;57:1654-62.
29. Peng H, Jiang X, Chen Y, Sojka DK, Wei H, et al. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. J
Clin Invest 2013;123:1444-56.
30. Nakano R, Ohira M, Yano T, Imaoka Y, Tanaka Y, et al. Hepatic irradiation persistently eliminates liver resident NK cells. PloS One
2018;13:e0198904.
31. Stegmann KA, Robertson F, Hansi N, Gill U, Pallant C, et al. CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells
residing in human liver. Sci Rep 2016;6:26157.
+
32. Bai L, Peng H, Hao X, Tang L, Sun C, et al. CD8 T cells promote maturation of liver-resident NK cells through the CD70-CD27 axis.
Hepatology 2019;70:1804-15.
33. Harmon C, Jameson G, Almuaili D, Houlihan DD, Hoti E, et al. Liver-derived TGF-beta maintains the Eomes(hi)Tbet(lo) phenotype
of liver resident natural killer cells. Front Immunol 2019;10:1502.
34. Zhou J, Peng H, Li K, Qu K, Wang B, et al. Liver-resident NK cells control antiviral activity of hepatic T cells via the PD-1-PD-L1
axis. Immunity 2019;50:403-17.e4.
35. Zhao ZB, Lu FT, Ma HD, Wang YH, Yang W, et al. Liver-resident NK cells suppress autoimmune cholangitis and limit the